Annexon becomes the latest group to provide a confusing update in the disease.
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.